# High dimensional morphology analysis reveals new insights in melanoma cell heterogeneity and enables label-free phenotyping

Evelyn Lattmann<sup>1</sup>, Aizhan Tastanova<sup>1</sup>, Andreja Jovic<sup>2</sup>, Manisha Ray<sup>2</sup>, Tiffine Pham<sup>2</sup>, Kevin B Jacobs<sup>2</sup>, Julie Kim<sup>2</sup>, Kevin B Jacobs<sup>2</sup>, Kevin B Jacobs<sup>2</sup>, Julie Kim<sup>2</sup>, Kevin B Jacobs<sup>2</sup>, Kevin B Jacobs<sup>2</sup>, Julie Kim<sup>2</sup>, Ju <sup>1</sup>University Hospital Zurich, Schlieren, Switzerland. <sup>2</sup>Deepcell Inc., Menlo Park, CA

## **KEY POINTS**

- The Deepcell platform characterizes & sorts cells based on multi-dimensional morphology analysis without labels, eliminating the need for specific biomarkers.
- We demonstrate that multi-dimensional morphology can distinguish mesenchymal vs melanocytic cells in both cell lines and dissociated tumor biopsies
- An AI-based random forest classifier can predict cell phenotype based on morphology alone, verified by single-cell transcriptional information

## INTRODUCTION

- Melanomas are the deadliest skin cancers, in part due to cellular plasticity and heterogeneity within the tumors.
- The Deepcell platform enables multi-dimensional morphology analysis and enrichment of unlabeled single cells using artificial intelligence (AI), advanced imaging, and microfluidics, enabling high resolution profiling of population heterogeneity.
- We imaged and analyzed 18 patient-derived melanoma cell lines representing both mesenchymal and melanocytic phenotypic states.
- High-dimensional morphological analysis showed distinct clusters for each phenotype, indicating distinct morphotype for each phenotype.
- We developed a random forest classifier to identify the top differential morphological features between the different cell lines, thereby providing a label-free means of phenotyping melanoma samples.
- The morphology analysis of the cell lines uncovered significant variability in pigmentation; a random forest classifier distinguished pigmented vs non-pigmented cells with >90% accuracy.
- Application of the classifier to images of dissociated tumor biopsies identified their phenotype, which was verified by scRNASeq, demonstrating the application of a label-free phenotyping using morphology alone in clinical samples.



## METHODS

**Figure 1. The Deepcell workflow.** We analyzed each of the sample types using the Deepcell Workflow. 1) Single cell suspension is (2) loaded onto a microfluidic chip. (3) Images of single cells are captured and analyzed in real-time by (4) deep learning and morphometric (computer vision) models to generate (5) multi-dimensional quantitative morphological profiles. User-defined cell clusters can be (6a) sorted for (7) downstream functional or molecular analysis. (6b) Morphology descriptions (embeddings) are extracted for data analysis/exploration and custom model training. The embeddings were used to profile the morphological heterogeneity of the cells, identify which morphology features differentiate each condition, and train a random forest classifier to predict each class of cells.

Visit our other posters: 1. Deepcell Platform [5381]

- 2. Deepcell AI & Data Science [5361]
- 3. Heterogeneous Tumor Subpopulation Enrichment [2392]
- 4. Malignant Effusion Tumor Cell Enrichment [LB170]





Figure 2. Multi-dimensional morphology distinguishes mesenchymal vs melanocytic cell lines. (A) 18 patient-derived cell lines from metastatic melanomas representing mesenchymal and melanocytic phenotypes were imaged and analyzed on the Deepcell platform. The phenotype of each cell line was based on mesenchymal or melanocytic gene expression signatures from bulk RNA-Seq data. (B) Images of cells indicate qualitative morphology differences detectable by eye, with melanocytic cells appearing smoother and mesenchymal cells are more granular. (C) Leiden clustering highlights the morphological diversity across the patient derived cell lines. (D) Multi-dimensional morphology UMAP showing distinct clusters for mesenchymal (orange) and melanocytic (green) cells, further illustrated by density plots. Inspection of the individual cell lines shows multiple morphotypes within each phenotype.





A 77.5 22.5 73.7 26.3 Melanocytic Mesenchymal **AI Classifier Prediction** D Mesenchymal vs Melanocytic Importance Feature LBP CENTER 09 3.04







### A random forest classifier can predict phenotype based on morphology alone

9.37

iction <b>L</b>	Sample: 150922, Transcriptional Label: Mes
elanocytic % of cells)	AI Prediction: Melanocytic
83.67	
84.15	
79.97	
79.15	AI Prediction: Mesenchymal
74.39	
2.97	
5.82	
8.99	Sample: 130604. Transcriptional Label: Mela
4.63	AT Prodiction: Molanocytic
60	
08	
19	
5.92	AI Prediction: Mesenchymal
1.98	
7.38	
1.59	
26	

### **RESULTS** cont.

Morphometrics features UMAP colored by Leiden clustering identifies a unique pigmented population. Representative images from each cluster are shown

## MNT-1 (high)



### **D** Top differential morphometric features

Non-pigmented vs pi	Non-pigmented vs pign				
Feature	In				
PERCENTILE_25					
NEGATIVE FRACTION					
MEAN					
PERCENTILE_75					
MIN_FERET					
PERIMETER					

scRNA-Seq verifies AI predictions of phenotype on melanoma DTCs						
•	DTC Sample ID	Tumor Location	Melanocytic Transcriptional Score	Mesenchymal Transcriptional Score	B (at a basic basi	
	11320	Lymph nodes	0.79	-0.30	- VHY 1	
-	20317	Metastatic tissue to lymph nodes	0.62	-0.39	- S 24 72020 80116 - 0	
	20720	Lymph nodes	0.80	-0.43		
	32221	Lymph nodes	0.74	-0.35	UMAP1 (scRNA-Seq data)	
-	71320	Lymph nodes	0.71	-0.37	DTC 20317 DTC 72020	
	71921	Lymph nodes	0.78	-0.51	Composition95% Tumor60% Tumor(scRNA-Seg)5% Immune40% Immune	
	72020	Lymph nodes	0.80	-0.31	Transcriptional Score 0.62 Melano, -0.39 Mesen, 0.8 Melano, -0.31 Mese	
-	80116	Axillary lymph node metastatic	0.79	-0.40	("Bulk" Analysis) Phenotype: Melanocytic Phenotype: Melanocytic	
		from melanoma			Classifier Prediction63% Melanocytic65% Melanocytic37% Mesenchymal35% Mesenchymal	

Figure 5. The phenotype classifier can predict the morphology of dissociated tumor biopsies. (A) The Melanoma Phenotype Classifier was run on dissociated tumor cell (DTC) samples, and AI predictions identified all DTCs as melanocytic. (B) We performed scRNA-Seq on the DTCs and the resulting UMAPs are shown. We analyzed the composition of the DTCs with sufficient malignant cell abundance for statistical analysis (labeled in blue). Results verified the AI predictions that the melanocytic phenotype was more prevalent in these samples.

## CONCLUSIONS

- phenotype with up to 77% accuracy

# **Cleepcell**



Figure 4. High dimensional morphology analysis reveals distinct pigmented subpopulation within melanoma cell lines. (A) Leiden clustering using morphometric features identified a population of pigmented cells (cluster 7). (B) Visual inspection and morphometric quantification of individual melanoma cell lines (MNT-1, 991104, SkMel-1) showed high, medium, and low pigmentation. (C) A random forest classifier using the morphometric features predict pigmented populations with up to 99% accuracy. (D) Top differential features distinguishing pigmented versus non-pigmented cells include pixel contrast and intensity values, as expressed by 25th/75th percentile of pixel grayscale values (Percentile\_25/75), negative fraction, and mean pixel intensity.

• High dimensional morphology analysis shows multiple morphotypes for melanocytic and mesenchymal cells • These morphological differences were used to develop a Melanoma Phenotype Classifier that can predict

• The morphometric features also identified a unique pigmented population with up to 99% accuracy

• The Melanoma Phenotype Classifier can be used to predict the phenotype of dissociated melanoma biopsies. • These results suggest that high dimensional morphology can be used to characterize phenotype in a label-free manner, and provide new insights into tumor biology.